THE RELATIONSHIP OF MEAN PLATELET VOLUME WITH NEUROPATHY IN TYPE 2 DIABETES MELLITUS

Öz

OBJECTIVE: Diabetic patients have an increased risk of developing micro and macrovascular complications. One of them is neuropathy, whose pathophysiological causes have not yet been absolutely understood. Platelet morphology and function are still been investigated about this topic. In this study we aimed to investigate the association of mean platelet volume with diabetic neuropathy. MATERIAL AND METHODS: Mean platelet volume levels were investigated and compared in type 2 diabetic patients with and without neuropathy and healthy participants. We then seeked the relation of mean platelet volume with hypertension, hyperlipidemia, hemoglobin A1c and body mass index in our diabetic patients. RESULTS: Mean platelet volume levels were the highest in our diabetic patients with neuropathy. In neuropaty negative and positive diabetic patients, existence of hypertension, hyperlipidemia and hypertension with hyperlipidemia did not changed mean platelet volume levels. Also mean platelet volume levels did not correlate with hemoglobin A1c and body mass index in all our groups. CONCLUSION: We think that large platelets may have an important role in complications of diabetes, especially in diabetic neuropathy. We may also say that in diabetics hypertension, hyperlipemia, obesity, control of diabetes were not related with mean platelet volume

Anahtar Kelimeler

• Neuropathy,Type 2 Diabetes Mellitus,Mean platelet volume

TİP 2 DİYABETES MELLİTUS HASTALARINDA ORTALAMA TROMBOSİT HACMİ İLE NÖROPATİ ARASINDAKİ İLİŞKİ

Öz

AMAÇ: Diyabetik hastalarda mikro ve makrovasküler komplikasyon gelişme riski yüksektir. Bunlardan biri, patofizyolojik nedeni henüz tam olarak anlaşılamamış olan nöropatidir. Trombosit morfoloji ve fonksiyonları bu konuyla ilgili olarak hala araştırılmaktadır. Bu çalışmada diyabetik nöropati ile ortalama trombosit hacmi arasındaki ilişkiyi incelemeyi planladık.GEREÇ VE YÖNTEMLER: Ortalama trombosit hacmi nöropatisi olmayan ve olan tip 2 diyabetik hastalarda ve sağlıklı kontrollerde araştırıldı ve karşılaştırıldı. Daha sonra diyabetik hastalarımızda ortalama trombosit hacmi ile hipertansiyon, hiperlipidemi, hemoglobin A1c ve vücut kitle indeksi arasında ilişki olup olmadığına baktık. BULGULAR: Ortalama trombosit hacmi nöropatisi olan diyabetik hastalarda en yüksek idi. Nöropatisi olan ve olmayan diyabetik hastalarda hipertansiyon, hiperlipidemi, hipertansiyon ile hiperlipidemi varlığı ortalama trombosit hacminde farklılık yaratmadı. Ayrıca gruplarımızda ortalama trombosit hacmi ile hemoglobin A1c ve vücut kitle indeksi arasında korelasyon yoktu.SONUÇ: Büyük trombositlerin diyabetik komplikasyonlarda özellikle nöropatide önemli bir rolü olabileceğini düşünüyoruz. Ayrıca diyabetiklerde hipertansiyon, hiperlipidemi, obezite, diyabetes kontrolünün ortalama trombosit hacmini ile ilişkili olmadığını düşünüyoruz

Anahtar Kelimeler

• Nöropati,Tip 2 Diyabetes Mellitus,Ortalama trombosit hacmi

Kaynakça

1. )Kamath S, Blann AD, Lip GY. Platelet activation: assess- ment and quantification. Eur Heart J. 2001; 22: 1561-71.
2. )Colwell JA. Vascular thrombosis in type II diabetes melli- tus. Diabetes. 1993; 42: 8-11.
3. )Erbaş T, Ertaş M, Yücel A, Keskinaslan A, Senocak M; TURNEP Study. Prevalence of peripheral neuropathy and painful peripheral neuropathy in Turkish diabetic patients. J Clin Neurophysiol. 2011; 8: 51-5.
4. )Kodiatte TA, Manikyam UK, Rao SB et al. Mean platelet volume in Type 2 diabetes mellitus. J Lab Physicians. 2012; : 5-9.
5. )Jindal S, Gupta S, Gupta R et al. Platelet indices in diabetes mellitus: indicators of diabetic microvascular complications. Hematology. 2011; 16: 86-9.
6. )Demirtunç R, Duman D, Başar M, Bilgi M, Teomete M, Garip T. The relationship between glycemic control and platelet activity in type 2 diabetes mellitus. J Diabetes Com- plications. 2009; 23: 89-94.
7. )Bavbek N, Kargılı A, Kaftan O, Karakurt F, Koşar A, Akçay A. Elevated concentrations of soluble adhesion molecules and large platelets in diabetic patients: Are they markers of vas- cular disease and diabetic nephropathy? Clin Appl Thromb Hemost. 2007; 13: 391-7.
8. )Mustand JF, Packham MA. Platelets and diabetes mellitus. New England J Med. 1984; 311: 665-7.

9. )Hekimsoy Z, Payzin B, Örnek T, Kandoğan G. Mean plate- let volume in type 2 diabetic patients. J Diabetes Complica- tions. 2004; 18: 173-6.
10. )Vinocour PD. Platelet abnormalities in diabetes mellitus. Diabetes. 1992; 41: 26-31.
11. )Tschoepe D, Roesen P, Esser J, Schwippert B, Nieuwen- huis HK, Kehrel B. Large platelets circulate in an activated state in diabetes mallitus. Semin Thromb Haemost. 1991; 17: 8.
12. )Sharpe PC, Thrink T. Mean platelet volume in diabetes mellitus. Q J Med. 1993; 86: 739-42.
13. )Jones RL, Paradise C, Peterson CM. Platelet survival in patients with diabetes mellitus. Diabetes. 1981; 30: 486-9.
14. )Cagliero E, Porta M, Cousins S, Kohner EM. Increased mean platelet volume in diabetic retinopathy. Haemostasis. : 12: 293-9. )Dindar S, Cinemre H, Sengül E, Annakaya AN. Mean platelet volume is associated with glycemic control and reti- nopathy in patients with type 2 di- abetes mellitus. West Indian Med L. 2013; 62: 519-23.
15. )Betteridge D, Zahavi J. Jones NAG, Shine B, Kakar VV, Galton DJ. Platelet function in diabetes mellitus in relation- ship to complications, glycosylated hemoglobin and serum lipoproteins. Eur J Clin Invest. 1981; 11: 273-7.
16. )Zhong ZL, Han M, Chen S. Risk factors associated with retinal neovascularisation of diabetic retinopathy in type 2 diabetes mellitus. Int J Ophtalmol. 2011; 4: 182-5.
17. )Tuzcu AE, Arıca S, İlhan N et al. Relationship between mean platelet volume and retinopathy in patients with type 2 diabetes. Graefes Arch Clin exp Ophtalmol. 2014; 252: 237-40.
18. )Demirin H, Ozhan H, Ucgun T, Celer A, Bulur S, Cil H. Normal range of mean platelet volume in healthy subjects: Insight from a large epidemiologic study. Thromb Res. 2011; : 358-60.
19. )Ünübol M, Ayhan M, Güney E. The relationship between mean platelet volume with microalbuminuria and glycemic control in patients with type II diabetes mellitus. Platelets. ; 23: 475-80. )Turgutalp K, Özhan O, Akbay E et al. Mean platelet vol- ume and related factors in patients at different stages of dia- betic nephropathy: A preliminary study. Appl Thromb He- most. 2014; 20: 190-5.
20. )Papanas N, Symonidis G, Maltezos E et al. Mean platelet volume with type 2 diabetes mellitus. Platelets. 2004; 15: 475-8.
21. )Shah B, Sha D, Xie D, Mohler ER, Berger JS. The relation- ship between diabetes, metabolic syndrome and platelet ac- tivity as measured by mean platelet volume. Diabetes Care. ; 35: 1074-8.
22. )Keskin S, Gürler M, Temeloğlu M, Çelebi A, Alicanoğlu R, Ekizoğlu I. Relation between mean platelet volume and risk factors for coronary heart disease. Turkiye Klinikleri J Med Sci. 2006; 26: 380-384.
23. )Zdrojewski Z, Lizakowski S, Raszeja-Specht A, Skibows- ka A, Rutkowski B. Influence of spontaneous thrombocyte aggregation on progression of glomerular disease. Nephron. )Yarlioglues M, Kaya MG, Ardic I et al. Relationship be- tween mean platelet volume levels and subclinical target or- gan damage in newly diagnosed hypertensive patients. Blood Pres. 2011; 20: 92-7.
24. )Bath PMW, Butterworth RJ. Platelet size: measurement, physiology and vascular disease. Blood Coagul Fibrinolysis. ; 7: 431-6. )Martin JF, Bath PMW, Burr ML. Influence of platelet size on outcome after myocardial infarction. Lancet. 1991; 338: 11.
25. )Pizzulli L, Yang A, Martin JF, Luderitz B. Changes in platelet size and count in unstable angina compared to stable angina or non-cardiac chest pain. Eur Heart J. 1998; 19: 80-4.
26. )Hendra TJ, Oswald GA, Yudkin YS. Increased mean platelet volume after acute myocardial infarction relates to diabetes and to cardiac failure. Diabetes Research and Clini- cal Practice. 1988; 5: 63-9.
27. ) Lalouschek W, Lang W, Müler M; Vienna Stroke study Group. Current strategies of secondary prevention after a cerebrovascular event: the Vienna stroke registry. Stroke. ; 32: 2860-6.
28. )Bennett PH. The diagnosis of diabetes: new international classification and diagnostic criteria. Annu Rev Med. 1983; : 295-309.
29. )Mancia G, De Backer G Dominiczak A et al. Management of arterial hypertension of the European Society of Hyper- tension, European Society of Cardiology, 2007 guidelines for the management of arterial hypertension. J Hypertens. 2007; : 1105-87.
30. )National Cholesterol Education Program. Detection, evaluation and treatment of high blood cholesterol in adults. Circulation. 2002: 106: 3145-421.
31. )Lauritzen T, Frost-Larsen K, Larsen HW, Deckert T. Two year experience with continous subcutaneous insulin in- fusiıon ln relation to retinopathy and neuropathy. Diabetes. ; 34: 74-9. )Satman I, Yilmaz T, Sengül A et al. Population based study of diabetes and risk characteristics in Turkey: results of the turkish diabetes epidemiology study (TURDEP). Diabetes Care. 2002; 25: 1551-6.
32. )Satman I, Omer B, Tutuncu Y et al. Twelve year trends in the prevaence and risk factors of diabetes and prediabetes in Turkish adults. Eur J Epidemiol. 2103; 28: 169-80.
33. )Zuberi BF, Akhtar N, Afsar S. Comparison of mean plate- let volume in patients with diabetes mellitus, impaired fasting glucose and non- diabetic subjects. Singapore Med J. 2008; : 114-6.
34. )Coban E, Bostan F, Özdoğan M. The mean platelet volume in subjects with impaired fasting glucose. Platelets. 2006; 17: 9.
35. )Shimodaire M, Niwa T, Nakajima K, Kobayashi M, Hanyu N, Nakayama T. Correlation between mean platelet volume and fasting plasma glucose levels in prediabetic and normo- glycemic individuals. Cardiovasc Diabetol. 2013; 12: 12-14.
36. )Shimodaire M, Niwa T, Nakajima K, Kobayashi M, Hanyu N, Nakayama T. Correlation between mean platelet volume and blood glucose levels after oral glucose loading in normo- glycemic and prediabetic Japanese subjects. J Diabetes Inves- tig. 2014; 5: 66-71.
37. )Coban E, Kucuktağ S, Basyiğit S. Platelet activation in subjects with impaired glucore tolerance. Platelets. 2007; 18: 4.
38. )Erikçi AA, Muhçu M, Dündar O, Öztürk A. Could mean platelet volume be a predictive marker for gestational diabe- tes. Hematology. 2008; 13: 46-8.
39. )Iyıdır OT, Degertekin CK, Yılmaz BA, Toruner FB, Akturk M, Aslan M. Elevated mean platelet volume is associated with gestational diabetes. Gynecol Endocrinol. 2014; 30: 640-3.
40. )Keating FK, Sobel BE, Schneider DJ. Effects of increased concentrations of glucose on platelet reactivity in healthy subjects and in patients with and without diabetes mellitus. Am J Cardiol. 2003; 92: 1362-5.
41. )Hara T, Nakamura J, Koh N et al. An aldolase reductase inhibitor TAT reduces ADP induced platelet hyperaggrega- tion in streptozotocin induced diabetic rats with neuropathy. J Lab Clin Med. 1995; 126: 541-7.
42. )UenoY, Koike H, Nakamura Y, Ochi Y, Annoch S, Nichio S. Effects of beroprost sodium, a prostacyclin analogue, on diabetic neuropathy in streptozotocin induced diabetic rats. Jpn j Pharmacol. 1996; 70: 177-82.
43. )O’Malley BC, Ward JD, Timberley WR, Porter NR, Pres- ton FE. Platelet abnormalities in diabetic peripheral neurop- athy. Lancet. 1975; 2: 1274-6.
44. )Jennings PE, Dallinger KJ, Nightingale S, Barnett AH. Ab- normal platelet aggregation in chronic symptomatic diabetic peripheral neuropathy. Diabet Med. 1986; 3: 237-40.
45. )Papanas N, Mavridis G, Karavageli E, Symeonidis G, Maltezos E. Peripheral neuropthy associated with increased mean platelet volume in type 2 diabetic patients. Platelets. )Xiao W, Huang Y, Dong J, Zhang X, Hu J. Relationship between platelet volume indices with macrovascular and peripheral neuropathy complications in type 2 diabetic pa- tients. J Diabetes. 2014; 6: 298-303.
46. )Martyn CN, Matthews DM, Popp-Snijders C, Tucker J, Ewing DJ, Clarke BF. Effects of sorbinil treatment on eryth- rocytes and platelets of persons with diabetes. Diabetes Care. ; 9: 36-9. )Watanabe Y, Kawada M, Kobayashi B. Effect of insulin on murine megacaryocytopoiesis in a liquid culture system. Cell Struct Funct. 1987; 12: 311-6.
47. )Guthikonda S, Alviar CL, Vaduganathan M et al. Role of reticulated platelets and platelet size heterogenity on platelet activity after dual antiplatelet therapy with aspirin and clopi- dogrel in patients with stable coronary artery disease. J Am Coll Cardiol. 2008; 52: 743-9.
48. )Ntaios G, Gürer O, Faouzi M, Aubert C, Michael P. Hy- pertension is an independent indicator of mean platelet vol- ume in patients with acute ischemic stroke. Intern Med J. ; 41: 691-5. )Cao X, Xie X, Zhou J, Yang P, Wang Y, Chen Z. Increased platelet volume in a general population with prehyperten- sion: a cross-sectional study of 80 545 participants from Chine. Hypertens Res. 2012; 35: 903-8.
49. )Coban E, Adanır H, Bilgin D. The association of mean platelet volume levels in hypertensive retinopathy. Platelets. ; 19: 115-8. )Bulur S, Önder HI, Aslantaş Y et al. Relation between indices of end-organ damage and mean platelet volume in hypertensive patients. Blood Coagul Fibrinolysis. 2012; 23: 9.
50. )Nufuez A, Gomez A, Zalba LR et al. Losartan inhibits in vitro platelet activation: comparison with candesartan and val- sartan. J Renin Angiotensin Aldosterone Syst. 2000; 1: 175-9.
51. )Bath P, Algert C, Chapman N, Neal B. PROGRESS Col- loborative Group. Association of mean platelet volume with risk of stroke among 3134 individuals with history of cere- brovascular disease. Stroke. 2004; 35: 622-6.
52. )Jagroop IA, Mikhailidis DP. Angiotensin II can induce and potentiate shape change in human platelets: effect of lo- sartan. J Hum Hypertens. 2000; 14: 581-5.
53. ) Verdoia M, Schaffer A, Barbieri L et al; Novara Athero- sclerosis Study (NAS) group. Diabetes, glucoe control and mean platelet volume: a single –centre cohort study. Diabetes Res Clin Pract. 2014; 104: 288-94.
54. )Bakovic D, Pivac N, Eterovic D et al. Changes in platelet size and spleen volume in response to selevtive and non-se- lective beta adrenoreceptor blockade in hypertensive pa- tients. Clin Exp Pharmacol Physiol. 2009; 36: 441-6.
55. )Çelik T, Yüksel UC, Iyisoy A et al. Effects of nebivolol on platelet activation in hypertensive patients: a comparative study with metoprolol. Int J Cardiol. 2007; 116: 206-11.
56. )Demirtunç R, Duman D, Başar M. Effect of doxazocin and amlodipine on mean platelet volume and serum serotonin level in patients with metabolic syndrome: a randomised, controlled study. Clin Drug Investig. 2007; 27: 435-41.
57. )Tschoepe D, Roesen P, Schwippert B, Gries FA. Platelets in diabetes .The role of hemostatic regulation in atherosclerosis. Semin Thromb Haemost. 1993; 19: 122-8.
58. )Park Y, Schoene N, Haris W. Mean platelet volume as an indicator of platelet activation: methodologicai issues. Plate- lets. 2002; 13: 301-6.
59. )Sivri N, Tekin G, Yatla K, Aksoy Y, Senen K, Yetkin E. Statins decrease mean platelet volume irrespective of choles- terol lowering effect. Kardiol Pol. 2013; 71: 1042-7.
60. )Mayer J, Eller T, Brauer P, et al. Effects of long term treat- ment with lovastatin on the clotting system ad blood trom- bosits. Ann Hematol. 1992; 64: 196-201.
61. )Bath PMW, Butterworth RJ. Platelet size: measurement, physiology and vascular disease. Blood Coagul Fibrinolysis. ; 7: 431-6. )Vinocour PD, Lopes-Virella MF, Laimins M, Colwell JA, Effect of insulin treatment in streptozocin induced diabetic rats on in vitro platelet function and plasma Von Willebrand factor activity and factor VIII related antigen. J Lab Clin Med. 1985; 106: 319-25.
62. )Vinocour PD, Kinlough-Rathbone RL, Mustard JF. Path- ways responsible for platelet hypersensitivity in rats with di- abetes. II. spontanous diabetes in BB Wistar rats. J Lab Clin Med. 1986; 107: 154-8.
63. )Tschoepe D, Ostermann H, Huebinger A, Ziegler D, Wiefels K, Gries FA. Elevated platelet activation in type 1 diabetics with chronic complications under long-term near normoglycemic control. Haemostasis. 1990; 20: 93-8.
64. ) Coban E, Özdoğan M, Yazıcıoğlu G, Akcit F. The mean platelet volume in patients with obesity. Int J Clin Pract. 2006; : 981-2.
65. )Muscari A, De Pascalis S, Cenni A et al. Determinants of mean platelet volume in an elderly population: relevance of body fat, blood glucose and ischemic electrocardiographic changes. Thromb Haemost. 2008; 99: 1079-84.
66. )Kutlucan A, Bulur S, Önder E et al. The relatioship be- tween mean platelet volume with metabolic syndrome in obese patients. Blood Coagul Fibrinolysis. 2012; 23: 388-90.
67. )Aypak C, Türedi O, Bircan MA, Yüce A. Could mean platelet volume among complete blood count parameters be a surrogate marker of metabolic syndrome in pre-pubertal children ? Platelets. 2014; 25: 393-8.
68. )Toplak H, Wascher TC. Influence on weight reduction on platelet volume: different effects of a hypocaloric diet and a very low diet. Eur J Clin Invest. 1994; 24: 778-80.
69. )Coban E, Yılmaz A, Sarı RE. The effect of weight loss on mean platelet volume in obese patients. Platelets. 2007; 18: 6.
70. )Arslan E, Yakar T, Yavaşoğlu I. The effect of smoking on mean platelet volume and lipid profile in young male sub- jects. Anadolu Kardiyol Derg. 2008; 8: 422-5.
71. )Butkiewicz AM, Kemona-Chetnik I, Dymicka-Pierkarska V, Matowicka-Karna J, Kemona H, Radiwon P. Does smoking affect thrombopoesis and platelet activation in women and men? Adv Med Sci. 2006; 51: 123-6.
72. )Biljak VR, Pancirov D, Cepelak I, Popovic-Grle S, Stje- panovic G, Grubisic TZ. Platelet count, mean platelet volume and smoking status in stable chronic obstructive pulmonary disease. Platelets. 2011; 22: 466-7.
73. )Kario K, Matsuo T, Nakao K. Cigarette smoking increases the mean platelet volume in elderly patients with risk factors for atherosclerosis. Clin Lab Haematol. 1992; 14: 281-7.
74. )Varol E, İcli A, Kocyiğit S, Erdoğan D, Özaydın M, Doğan A. Effect of smoking cessation on mean platelet volume. Clin Appl Thromb Hemost. 2103; 19: 315-9.
75. )Yarlioglues M, Ardic I, Dogdu O et al. The acute effects of passive smoking on mean platelet volume in healthy volun- teers. Angiology. 2012; 63: 353-7.
76. )Liu C, Yang Y, He M et al. Passive smoke exposure was re- lated to mean platelet volume in never smokers. Am J Health Behav. 2014; 38: 519-28.
77. )Dolaşık İ, Sener SY, Çelebi K, Aydın ZM, Korkmaz U, Cantürk Z. The effect of metformin on mean platelet volume in diabetic patients. Platelets. 2012; 24: 118-21.
78. )Vernekar PV, Vaidya KA. Comparison of mean platelet volume in type 2 diabetics on insulin therapy and on oral hy- poglycemic agents. J Clin Diagn Res. 2013; 7: 2839-40.